Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

McGuirk

Showing results (511-520 of 583) with videos related to

Pageof 59
Sort By:
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Transplantation and Cellular Therapy|July 25, 2022
Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell TransplantationSeth J Rotz, Jean C Yi, Betty K Hamilton, et al.
Blood|November 1, 2021
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamideEphraim J Fuchs, Shannon R McCurdy, Scott R Solomon, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Blood|June 22, 2021
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized studyMitchell E Horwitz, Patrick J Stiff, Corey Cutler, et al.
Haematologica|December 6, 2018
Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivorsNavneet S Majhail, Elizabeth Murphy, Purushottam Laud, et al.
Blood Advances|February 25, 2020
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantationDaniel Weisdorf, Sarah Cooley, Tao Wang, et al.
Transplantation and Cellular Therapy|March 4, 2023
Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple MyelomaRajshekhar Chakraborty, Jean Yi, Lisa Rybicki, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Transplantation and Cellular Therapy|September 11, 2024
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA AntibodiesPiyanuch Kongtim, Pongthep Vittayawacharin, Jun Zou, et al.
Pageof 59

Showing results (511-520 of 583) with videos related to

Sort By:
Pageof 59
Transplantation and Cellular Therapy|September 19, 2025
Fludarabine Lymphodepletion Exposure is Associated with Toxicities after Idecabtagene-Vicleucel in Relapsed/Refractory Multiple Myeloma: Real-World Experience from the US Myeloma Immunotherapy ConsortiumKaren Sweiss, Charlotte Wagner, Eric Anto, et al.
Transplantation and Cellular Therapy|July 25, 2022
Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell TransplantationSeth J Rotz, Jean C Yi, Betty K Hamilton, et al.
Blood|November 1, 2021
HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamideEphraim J Fuchs, Shannon R McCurdy, Scott R Solomon, et al.
Haematologica|October 19, 2023
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experienceHamza Hashmi, Doris K Hansen, Lauren C Peres, et al.
Blood|June 22, 2021
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized studyMitchell E Horwitz, Patrick J Stiff, Corey Cutler, et al.
Haematologica|December 6, 2018
Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivorsNavneet S Majhail, Elizabeth Murphy, Purushottam Laud, et al.
Blood Advances|February 25, 2020
KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantationDaniel Weisdorf, Sarah Cooley, Tao Wang, et al.
Transplantation and Cellular Therapy|March 4, 2023
Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple MyelomaRajshekhar Chakraborty, Jean Yi, Lisa Rybicki, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Transplantation and Cellular Therapy|September 11, 2024
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA AntibodiesPiyanuch Kongtim, Pongthep Vittayawacharin, Jun Zou, et al.
Pageof 59